The BreastTrue High Risk Panel is best suited for individuals with either a history of early onset breast or ovarian cancer or a strong family history of breast and/or ovarian cancer. Individuals with the following medical or family history factors should consider testing:
- Early onset breast cancer (under 50 years of age)
- Bilateral or multiple breast cancers
- Diagnosed with both breast and ovarian cancer
- Family history of breast and/or ovarian cancer
BreastTrue High Risk Panel is a next-generation sequencing test that detects mutations in eight high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2. In addition, the test includes deletion/duplication analysis of the BRCA1/2 genes by MLPA.
Recent studies of breast cancer survivors have shown that approximately 70 percent of the mutations identified were BRCA1/2 mutations. Approximately 4 percent had germline mutations in other cancer-susceptibility genes, including high-risk genes. These additional high-risk genes include CDH1, CHEK2, PALB2, PTEN, STK11, and TP53.